多发性骨髓瘤中对CAR-T细胞疗法耐药的机制：2024年美国血液学会年会的最新进展
Mechanisms of resistance to CAR-T cell therapy in multiple myeloma: latest updates from the 2024 ASH annual meeting.
作者信息
Hu Yuhan, Hou Jiangxue, Jiang Zhongxing, Lin Quande
机构信息
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, China.
The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China.
出版信息
Exp Hematol Oncol. 2025 Mar 26;14(1):45. doi: 10.1186/s40164-025-00643-6.
Abstract
Chimeric Antigen Receptor T-Cell (CAR-T) therapy demonstrates significant potential in the treatment of multiple myeloma (MM). However, resistance to CAR-T therapy remains a critical challenge. Investigating the mechanisms underlying CAR-T resistance, including antigen escape, immunosuppression, and CAR-T cell exhaustion, is essential for enhancing the long-term efficacy of this therapeutic approach. This study provides an in-depth review of the latest findings presented at the 66th ASH Annual Meeting.
摘要
嵌合抗原受体T细胞（CAR-T）疗法在多发性骨髓瘤（MM）治疗中显示出巨大潜力。然而，对CAR-T疗法的耐药性仍然是一个关键挑战。研究CAR-T耐药的潜在机制，包括抗原逃逸、免疫抑制和CAR-T细胞耗竭，对于提高这种治疗方法的长期疗效至关重要。本研究深入回顾了在第66届美国血液学会年会上发表的最新研究成果。
相似文献
1
Mechanisms of resistance to CAR-T cell therapy in multiple myeloma: latest updates from the 2024 ASH annual meeting.多发性骨髓瘤中对CAR-T细胞疗法耐药的机制：2024年美国血液学会年会的最新进展
Exp Hematol Oncol. 2025 Mar 26;14(1):45. doi: 10.1186/s40164-025-00643-6.
2
Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting.血液系统恶性肿瘤的新型细胞免疫疗法：2021年美国血液学会年会的最新进展
Exp Hematol Oncol. 2022 Sep 24;11(1):61. doi: 10.1186/s40164-022-00316-8.
3
BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting.用于多发性骨髓瘤的靶向BCMA疗法：2024年美国血液学会年会的最新进展
J Hematol Oncol. 2025 Mar 1;18(1):23. doi: 10.1186/s13045-025-01675-5.
4
Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting.针对复发或难治性多发性骨髓瘤的 GPRC5D 免疫疗法：2022 年 ASH 年会的最新进展。
J Hematol Oncol. 2023 Jun 5;16(1):60. doi: 10.1186/s13045-023-01461-1.
5
Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting.用于复发/难治性B细胞恶性肿瘤的新型嵌合抗原受体T细胞疗法：2023年美国血液学会年会的最新进展
Exp Hematol Oncol. 2024 Apr 18;13(1):43. doi: 10.1186/s40164-024-00508-4.
6
BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting.BCMA 靶向 CAR-T 细胞疗法治疗复发和/或难治性多发性骨髓瘤：2023 年 ASCO 年会最新进展。
J Hematol Oncol. 2023 Jul 28;16(1):86. doi: 10.1186/s13045-023-01479-5.
7
Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meeting.用于血液系统恶性肿瘤的双靶点嵌合抗原受体T细胞免疫疗法：2023年美国血液学会年会的最新进展
Exp Hematol Oncol. 2024 Feb 27;13(1):25. doi: 10.1186/s40164-024-00485-8.
8
Mechanisms underlying resistance to CAR-T cell therapy and strategies for enhancement.嵌合抗原受体（CAR）-T细胞疗法耐药的潜在机制及增强策略。
Cytokine Growth Factor Rev. 2025 Jun;83:66-76. doi: 10.1016/j.cytogfr.2025.04.002. Epub 2025 Apr 22.
9
Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma.嵌合抗原受体 (CAR) T 细胞疗法治疗多发性骨髓瘤。
Pharmacol Ther. 2022 Apr;232:108007. doi: 10.1016/j.pharmthera.2021.108007. Epub 2021 Sep 25.
10
Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting.靶向 BCMA 治疗多发性骨髓瘤：2021 年 ASH 年会更新。
Front Immunol. 2022 Mar 7;13:839097. doi: 10.3389/fimmu.2022.839097. eCollection 2022.
引用本文的文献
1
Deciphering the bone marrow microenvironment's role in multiple myeloma immunotherapy resistance.解读骨髓微环境在多发性骨髓瘤免疫治疗耐药中的作用
Front Immunol. 2025 Jul 18;16:1613265. doi: 10.3389/fimmu.2025.1613265. eCollection 2025.
2
Lapatinib-Resistant HER2+ Breast Cancer Cells Are Associated with Dysregulation of MAPK and p70S6K/PDCD4 Pathways and Calcium Management, Influence of Cryptotanshinone.拉帕替尼耐药的HER2+乳腺癌细胞与MAPK和p70S6K/PDCD4信号通路失调及钙管理有关，隐丹参酮的影响
Int J Mol Sci. 2025 Apr 16;26(8):3763. doi: 10.3390/ijms26083763.
本文引用的文献
1
Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy.BCMA 嵌合抗原受体 T 细胞治疗后复发的多发性骨髓瘤患者的机制和挽救治疗。
Front Immunol. 2024 Oct 22;15:1433774. doi: 10.3389/fimmu.2024.1433774. eCollection 2024.
2
PD1TIGIT2B4KLRG1 Cells Might Underlie T Cell Dysfunction in Patients Treated with BCMA-Directed Chimeric Antigen Receptor T Cell Therapy.接受 BCMA 导向嵌合抗原受体 T 细胞疗法治疗的患者中，PD1TIGIT2B4KLRG1 细胞可能是 T 细胞功能障碍的基础。
Transplant Cell Ther. 2024 Feb;30(2):191-202. doi: 10.1016/j.jtct.2023.11.014. Epub 2023 Nov 14.
3
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma.双等位基因 BCMA 缺失导致多发性骨髓瘤患者对 CAR T 细胞治疗产生耐药。
Nat Commun. 2021 Feb 8;12(1):868. doi: 10.1038/s41467-021-21177-5.
4
γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.γ-分泌酶抑制增强了 BCMA 特异性嵌合抗原受体 T 细胞在多发性骨髓瘤中的疗效。
Blood. 2019 Nov 7;134(19):1585-1597. doi: 10.1182/blood.2019000050.
Zotero 插件